Maravai LifeSciences Holdings Inc. Class A Common Stock vs NetApp Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while NetApp Inc. trades at $218.8 (market cap $46.95B). The key difference: NetApp Inc. is far larger — about 48.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and NetApp Inc. pays a 0.87% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NetApp Inc. for 57 Days on average.
| MRVI | NTAP | |
|---|---|---|
Market Cap | $972.90M | $46.95B |
Volume | 4,325,710 | 2,358,705 |
Sector | Health | Technology |
52-Week High | $9.00 | $239.23 |
52-Week Low | $2.83 | $94.11 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $1.08B | $45.90B |
Dividend Yield | — | 0.87% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NetApp (NTAP) trades at $222.2, down 7.12% over the past day, yet maintains a strong fundamental profile with robust profitability margins and consistent earnings beats. The stock exhibits a bullish technical signal, supported by moving averages, though oscillators indicate potential overbought conditions. Recent strategic announcements at INSIGHT 2026, including AI infrastructure partnerships and new product launches, highlight the company's focus on capitalizing on data and AI-driven demand.
The outlook for NTAP is positive, driven by solid earnings growth, strategic AI initiatives, and favorable analyst sentiment, but risks include high valuation multiples, competitive pressures in the storage sector, and macroeconomic sensitivity. The consensus price target of $219.30 suggests limited near-term upside from current levels, warranting caution amid recent volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →